Platelet to lymphocyte ratio as a predictive factor of 30-day mortality in patients with acute mesenteric ischemia.
Aged
Aged, 80 and over
Biomarkers
/ blood
Blood Platelets
/ cytology
Female
Humans
Lymphocyte Count
Lymphocytes
/ cytology
Male
Mesenteric Ischemia
/ blood
Middle Aged
Mortality
Neutrophils
/ cytology
Patient Admission
Platelet Count
Predictive Value of Tests
Prognosis
Retrospective Studies
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
04
2019
accepted:
02
07
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
10
3
2020
Statut:
epublish
Résumé
Acute mesenteric ischemia is associated with high rates of mortality. The aim of this study was to investigate the prognostic value of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) on 30-day outcomes in patients with acute mesenteric ischemia. Consecutive patients who were admitted for an acute mesenteric ischemia were retrospectively included. The full white blood count at the time of admission to the hospital was recorded. The population was divided into 4 subgroups according to the quartiles of the NLR and the PLR. The 30-day outcomes including the mortality and the complications were compared among the subgroups. In total, 106 patients were included. A surgical treatment including revascularization and/or digestive resection was performed for 56 patients (52.8%). The 30-day all-cause mortality was 72 patients (67.9%). Patients with higher PLR value (PLR >429.3) had significantly higher rate of mortality compared to the other groups (80.8% vs 46.2%, 66.7% and 77.8%, p = 0.03). No significant difference on 30-day outcome was observed among the subgroups divided according to the NLR. The PLR, but not the NLR, is a predictive factor of 30-day mortality in patients with acute mesenteric ischemia.
Identifiants
pubmed: 31314768
doi: 10.1371/journal.pone.0219763
pii: PONE-D-19-12218
pmc: PMC6636734
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0219763Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Oncotarget. 2017 Sep 27;8(51):88835-88844
pubmed: 29179480
Angiology. 2016 Jan;67(1):89-95
pubmed: 25922197
Ulus Travma Acil Cerrahi Derg. 2017 Jul;23(4):301-305
pubmed: 28762450
Blood Coagul Fibrinolysis. 2016 Mar;27(2):127-30
pubmed: 26258672
Curr Opin Rheumatol. 1998 Sep;10(5):417-25
pubmed: 9746856
Br J Surg. 2004 Aug;91(8):991-4
pubmed: 15286959
Ulus Travma Acil Cerrahi Derg. 2011 May;17(3):193-8
pubmed: 21935794
Biomark Med. 2016 Oct;10(10):1061-1072
pubmed: 27690543
Angiology. 2018 Sep;69(8):686-691
pubmed: 29334754
Best Pract Res Clin Gastroenterol. 2017 Feb;31(1):69-74
pubmed: 28395790
Am J Cardiol. 2008 Mar 15;101(6):747-52
pubmed: 18328833
Neurol Res. 2016 Sep;38(9):759-65
pubmed: 27477691
Vasc Endovascular Surg. 2019 Jan;53(1):5-11
pubmed: 30021492
Br J Surg. 1995 Nov;82(11):1446-59
pubmed: 8535792
Am J Cardiol. 2008 Sep 15;102(6):653-7
pubmed: 18773982
Mod Rheumatol. 2016;26(3):372-6
pubmed: 26403379
Eur J Trauma Emerg Surg. 2016 Jun;42(3):363-8
pubmed: 26059561
J Stroke Cerebrovasc Dis. 2019 Jan;28(1):76-83
pubmed: 30268367
Intern Emerg Med. 2017 Sep;12(6):821-836
pubmed: 28478489
Ulus Travma Acil Cerrahi Derg. 2016 Jul;22(4):344-9
pubmed: 27598606
Postepy Kardiol Interwencyjnej. 2017;13(1):32-38
pubmed: 28344615
Ann Vasc Surg. 2018 May;49:115-122
pubmed: 29428537
Scand J Clin Lab Invest. 2008;68(3):242-8
pubmed: 17934974
Int J Surg. 2012;10(9):510-3
pubmed: 22885139
J Vasc Surg. 2014 Sep;60(3):661-8
pubmed: 24816510
World J Emerg Surg. 2017 Aug 7;12:38
pubmed: 28794797
Am Heart J. 2007 Nov;154(5):995-1002
pubmed: 17967611
Pak J Med Sci. 2017 Nov-Dec;33(6):1366-1370
pubmed: 29492060
Langenbecks Arch Surg. 2008 Mar;393(2):163-71
pubmed: 18172675